ARK Genomic Revolution ETF vs Impinj Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.89, while Impinj Inc trades at $146.93 (market cap $4.39B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | PI | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $241.91 |
52-Week Low | $23.09 | $91.34 |
Market Cap | — | $4.39B |
Enterprise Value | — | $4.52B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Impinj (PI) trades at $144.03, down 0.26% today, with a bullish technical signal supported by moving averages and a golden cross pattern. The company reported Q1 2026 earnings of $0.14 per share, beating estimates, but faces negative net income margins and high valuation multiples. Recent news highlights insider selling and upcoming Q2 2026 results, while analyst consensus remains strongly bullish with a $167.50 price target.
The outlook for PI is mixed: strong analyst support and technical momentum suggest upside potential, but profitability challenges and high valuations pose risks. Investment opportunity hinges on execution improving margins and revenue growth, while key risks include competitive pressures and insider selling trends.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →